Figure 11 Antitumor activity evaluation of 3BP-LCNP-FA in vivo. (A) Formation of tumors in control, LCNP-FA, 3BP, 3BP-LCNP, and 3BP-LCNP-FA groups of mice. After nude mice were sacrificed in the last administration, tumor weights of different dosage groups were analyzed. (B) Data are presented as mean±S.D. (n=4) * P<0.05, ** P<0.01. (C) Change curves of mice weight and (D) tumor volume were measured at different time points after administration of different dosage forms. Data are presented as mean±S.D. (n=4). H &E staining of the tumors, lung, liver, and kidney after LCNP-FA, 3BP, 3BP-LCNP, and 3BP-LCNP-FA treatment vs. control. (E) The images are representative of three independent experiments. After LCNP-FA, 3BP, 3BP-LCNP, and 3BP-LCNP-FA treatment, the levels of AST, ALT, Cr, and BUN were evaluated by taking orbital venous blood. (F) Data represent the Mean±S.D. (n=6). PCNA immunohistochemistry of LCNP, 3BP, 3BP-LCNP, and 3BP-LCNP-FA treatment. (G) The images are representative of three independent experiments. TUNEL assay of LCNP, 3BP, 3BP-LCNP, and 3BP-LCNP-FA treatment. (H) The images are representative of three independent experiments.